BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37489911)

  • 1. Design and Execution of Sustainable Decentralized Clinical Trials.
    Singh P; Burden AM; Natanegara F; Beckman RA
    Clin Pharmacol Ther; 2023 Oct; 114(4):802-809. PubMed ID: 37489911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance.
    Park J; Huh KY; Chung WK; Yu KS
    Transl Clin Pharmacol; 2024 Mar; 32(1):41-51. PubMed ID: 38586122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decentralized clinical trials (DCTs): A few ethical considerations.
    Petrini C; Mannelli C; Riva L; Gainotti S; Gussoni G
    Front Public Health; 2022; 10():1081150. PubMed ID: 36590004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethics review of decentralized clinical trials (DCTs): Results of a mock ethics review.
    van Rijssel TI; de Jong AJ; Santa-Ana-Tellez Y; Boeckhout M; Zuidgeest MGP; van Thiel GJMW;
    Drug Discov Today; 2022 Oct; 27(10):103326. PubMed ID: 35870693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ethics of Decentralized Clinical Trials and Informed Consent: Taking Technologies' Soft Impacts into Account.
    van Rijssel TI; van Thiel GJMW; van Delden JJM;
    Health Care Anal; 2024 May; ():. PubMed ID: 38764063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legal, Regulatory, and Practical Issues to Consider When Adopting Decentralized Clinical Trials: Recommendations From the Clinical Trials Transformation Initiative.
    Apostolaros M; Babaian D; Corneli A; Forrest A; Hamre G; Hewett J; Podolsky L; Popat V; Randall P
    Ther Innov Regul Sci; 2020 Jul; 54(4):779-787. PubMed ID: 32557302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment.
    Betcheva L; Kim JY; Erhun F; Oraiopoulos N; Getz K
    Ther Innov Regul Sci; 2023 Sep; 57(5):1081-1098. PubMed ID: 37389795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective.
    de Jong AJ; Shahid N; Zuidgeest MGP; Santa-Ana-Tellez Y; Hogervorst M; Goettsch W; Traore H; de Boer A; Gardarsdottir H;
    Value Health; 2024 Mar; 27(3):294-300. PubMed ID: 38043711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Financial Value of Decentralized Clinical Trials.
    DiMasi JA; Smith Z; Oakley-Girvan I; Mackinnon A; Costello M; Tenaerts P; Getz KA
    Ther Innov Regul Sci; 2023 Mar; 57(2):209-219. PubMed ID: 36104654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs).
    Coyle J; Rogers A; Copland R; De Paoli G; MacDonald TM; Mackenzie IS;
    Trials; 2022 Jul; 23(1):614. PubMed ID: 35907888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Internet of Medical/Health Things to Decentralized Clinical Trials: Development Status and Regulatory Considerations.
    Sato T; Ishimaru H; Takata T; Sasaki H; Shikano M
    Front Med (Lausanne); 2022; 9():903188. PubMed ID: 35733872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation status and consideration for the globalisation of decentralised clinical trials: a cross-sectional analysis of clinical trial databases.
    Sato T; Mizumoto S; Ota M; Shikano M
    BMJ Open; 2023 Oct; 13(10):e074334. PubMed ID: 37821130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of remote data capture, wearables, and digital biomarkers in decentralized clinical trials.
    Chodankar D; Raval TK; Jeyaraj J
    Perspect Clin Res; 2024; 15(1):38-41. PubMed ID: 38282631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges.
    Sinha SD; Chary Sriramadasu S; Raphael R; Roy S
    Pharmaceut Med; 2024 Mar; 38(2):109-120. PubMed ID: 38453755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decentralized Clinical Trials in the Development of Drugs and Biological Products.
    Robinson R; Sacks L
    Ther Innov Regul Sci; 2024 Feb; ():. PubMed ID: 38305983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing asthma research and improving health equity through decentralized clinical trials (DCTs) and mHealth technology.
    Hunt ER; Hantgan SL; Jariwala SP
    J Asthma; 2024 Apr; 61(4):265-270. PubMed ID: 37787433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.
    Korczak D; Dietl M; Steinhauser G
    GMS Health Technol Assess; 2011 Apr; 7():Doc02. PubMed ID: 21468290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective.
    de Jong AJ; van Rijssel TI; Zuidgeest MGP; van Thiel GJMW; Askin S; Fons-Martínez J; De Smedt T; de Boer A; Santa-Ana-Tellez Y; Gardarsdottir H;
    Clin Pharmacol Ther; 2022 Aug; 112(2):344-352. PubMed ID: 35488483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.